Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies | Zendy

Udai Banerji | Zendy; Anne O’Donnell | Zendy; Michelle Scurr | Zendy; Simon Pacey | Zendy; Sarah Stapleton | Zendy; Yasmin J. Asad | Zendy; Laura K. Simmons | Zendy; Alison Maloney | Zendy; Florence I. Raynaud | Zendy; Maeli Campbell | Zendy; Michael I. Walton | Zendy; Sunil R. Lakhani | Zendy; Stanley B. Kaye | Zendy; Paul Workman | Zendy; Ian Judson | Zendy

Open Access

Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies

Author(s) -

Udai Banerji,

Anne O’Donnell,

Michelle Scurr,

Simon Pacey,

Sarah Stapleton,

Yasmin J. Asad,

Laura K. Simmons,

Alison Maloney,

Florence I. Raynaud,

Maeli Campbell,

Michael I. Walton,

Sunil R. Lakhani,

Stanley B. Kaye,

Paul Workman,

Ian Judson

Publication year - 2005

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2005.00.612

Subject(s) - medicine , pharmacokinetics , pharmacodynamics , dosing , toxicity , gastroenterology , area under the curve , pharmacology

To study the toxicity and pharmacokinetic-pharmacodynamic profile of 17-allylamino, 17- demethoxygeldanamycin (17-AAG) and to recommend a dose for phase II trials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Address

About

Learn

Download the Zendy App

Discover

Explore